For example, data from the CROWN trial showed that approximately 90% of ALK-positive NSCLC patients treated with lorlatinib were alive at 12 months, compared to only about 40% of patients in the broader metastatic NSCLC population[8]. This evidence concerns the gene ALK and non-small cell lung carcinoma.